Reprogramming Gamma Delta T Cells Into Induced Pluripotent Stem Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for reprogramming somatic cells into pluripotent stem cells face challenges, particularly in efficiency and the need for improved materials and techniques that avoid ethical concerns associated with embryonic stem cell derivation.

Innovation Solution

The method involves contacting isolated cells with an activation culture containing IL-15 and zoledronic acid to enrich and activate γδ T cells, followed by transduction with a viral vector encoding reprogramming factors, such as OCT3/4, SOX2, KLF4, and c-Myc, to induce pluripotency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional reprogramming methods are used to generate iPSCs, then pluripotent stem cells can be produced, but the efficiency of reprogramming is low

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidtime for iPSC generation

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-activating γδ T cells with IL-15 and zoledronic acid before introducing reprogramming factors. This activation step prepares the cells in advance, making them more receptive to reprogramming and significantly improving efficiency compared to direct reprogramming of non-activated cells.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the physiological state parameters of the target cells by using specific cytokine concentrations (IL-15 at 50-500 ng/mL) and drug treatments (zoledronic acid at 1-10 μg/mL) to create an optimal activation state that enhances reprogramming efficiency and reduces the time required.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If embryonic stem cell derivation is used, then pluripotent stem cells can be obtained, but ethical concerns arise

Engineering Contradiction:

Improvepluripotency qualityVSAvoidethical concerns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses γδ T cells as an intermediary cell type that can be reprogrammed into iPSCs without involving embryos. This intermediary approach achieves the desired pluripotent stem cells while avoiding the ethical controversies associated with embryonic destruction, maintaining reliability through proven reprogramming factors.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of manufacture

If standard reprogramming protocols are applied, then iPSCs can be generated, but feeder cell dependency limits scalability

Engineering Contradiction:

ImproveiPSC production simplicityVSAvoidculture system complexity

Core Design Contradiction:

Ease of manufactureVSDevice complexity

Solution Approach 1:

The patent extracts the feeder cell dependency from the culture system by optimizing conditions that enable feeder-free growth of γδ T cell-derived iPSCs. This removal simplifies the overall system, eliminating the need for separate feeder cell maintenance and reducing contamination risks while improving scalability.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20240360421A1Materials and methods for the manufacture of pluripotent stem cells

Publication Date: 2024.10.31 JANSSEN BIOTECH INC

AI summary

Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.